Comparison of CD34+ cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy

Humpe, Andreas; Riggert, Joachim; Vehmeyer, K.; Troff, C.; Hiddemann, W.; Köhler, Michael; Wörmann, Bernhard

doi:10.1046/j.1537-2995.1997.371098016444.x

Cited by 38 publications

(43 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,6,7 However, the results reported showed that viable CD34 þ cells after cryopreservation did not decrease but instead increased by up to 77%. 5 In addition, the reported viability of CD34 þ cells varied from 0 to 304%.…”

Section: Cd34mentioning

confidence: 92%

“…þ cell number and colony growth before and after cryopreservation of peripheral hematopoietic progenitor cells (HPC), 4,5 and concluded that post-thaw CD34 þ cell number may be useful in monitoring cell loss during cryopreservation. 4,6,7 However, the results reported showed that viable CD34 þ cells after cryopreservation did not decrease but instead increased by up to 77%.…”

Section: Cd34mentioning

confidence: 99%

“…5 In addition, the reported viability of CD34 þ cells varied from 0 to 304%. 4,8 This wide variation of the post-cryopreservation viability resulted from the post-thaw assessment assays being based on the number of nucleated cells remaining after cryopreservation. 9,10 However, the number of nucleated cells, particularly neutrophils, is decreased during cryopreservation and during post-thaw incubation due to cell loss and clumping of the damaged cells.…”

Section: Cd34mentioning

confidence: 99%

“…However, the inevitable loss of CD34 þ cells between collection and transplant, especially during cryopreservation, is difficult to predict without assessment of the sample after cryopreservation. 4,5,7,8,18 This leads to the current debate as to whether the quantification of HPC should be performed before or after cryopreservation.…”

Section: Cd34mentioning

confidence: 99%

See 3 more Smart Citations

Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment

Yang

Acker

Cabuhat

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:In all, 78 peripheral hematopoietic progenitor cell collections from 52 patients were evaluated using our previously published validated post-thaw assays at the time of collection and following transplantation by assessment of viable CD34 þ cells, and granulocytemacrophage colony-forming units (CFU-GM) cryopreserved in quality control vials. The median (range) post-thaw recovery of viable CD34 þ cells and CFU-GM was 66.4% (36.1-93.6%) and 63.0% (28.6-85.7%), respectively, which did not show significant correlation with the engraftment of either neutrophils (P ¼ 0.136 and 0.417, respectively) or platelets (P ¼ 0.88 and 0.126, respectively). However, the reinfused viable CD34 þ cells/ kg of patient weight pre-or post-cryopreservation showed significant correlation to engraftment of neutrophils (P ¼ 0.0001 and 0.001, respectively) and platelets (P ¼ 0.023 and 0.010, respectively), whereas CFU-GM pre-or post-cryopreservation was significantly correlated to neutrophils (P ¼ 0.011 and 0.007, respectively) but not to platelets (P ¼ 0.112 and 0.100, respectively). The results show that post-cryopreservation assessment of viable CD34 þ cells or CFU-GM is as reliable a predictor of rapid engraftment as that of pre-cryopreservation measures. Therefore, the post-cryopreservation number of viable CD34 þ cells or CFU-GM should be used to eliminate the risks of unforeseen cell loss that could occur during cryopreservation or long-term storage.

show abstract

Section: Cd34mentioning

confidence: 92%

Section: Cd34mentioning

confidence: 99%

Section: Cd34mentioning

confidence: 99%

Section: Cd34mentioning

confidence: 99%

See 2 more Smart Citations

Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment

Yang

Acker

Cabuhat

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…These have disagreed over the influence of age, [1][2][3][4] gender, [4][5][6] interval from last chemotherapy, 1,3,4,7,8 bone marrow involvement, 1,3,4,8,9 tumor primary, 5,9,10 disease status, [3][4][5] and prior radiation, 3,4,9,11,12 suggesting that these are, at best, weak predictive factors. Overall, however, one of the most consistent negative influences on mobilization efficiency has been the amount of prior chemotherapy.…”

Section: Motherapy; Cd34mentioning

confidence: 99%

Effect of prior chemotherapy on hematopoietic stem cell mobilization

Ford

Green

Warenski

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:A number of studies have suggested that prior chemotherapy correlates negatively with the efficiency of hematopoietic stem cell mobilization. However, little data exist with regard to the relative effects of the specific chemotherapeutic drug classes. We retrospectively reviewed the records of 201 consecutive patients with nonmyeloid malignancies undergoing CD34 þ cell mobilization with chemotherapy þ granulocyte colony-stimulating factor (G-CSF). The number of prior chemotherapy courses correlated negatively with the peripheral CD34 þ cell concentration (pCD34) on the first day of collection (Po0.001). No significant correlation was found for age, gender, tumor primary, mobilization chemotherapy regimen, disease status, marrow involvement, prior radiation therapy, or dose and timing of G-CSF administration. When the number of courses of individual classes of chemotherapeutic agents was correlated with pCD34, only exposures to platinum compounds (P ¼ 0.001) and alkylating agents (P ¼ 0.01) were found to be independent negative predictive factors for pCD34. Within classes, DNA crosslinking agents and etoposide appeared possibly more damaging than DNA methylating agents and doxorubicin, respectively. None of the drug classes showed evidence of recovery. We conclude that exposure to chemotherapy, especially platinum compounds and alkylating agents, should be minimized prior to mobilization.

show abstract

Cryopreservation of hematopoietic stem cells

et al. 2007

View full text Add to dashboard Cite

Stem cell transplantation represents a critical approach for the treatment of many malignant and non-malignant diseases. The foundation for these approaches is the ability to cryopreserve marrow cells for future use. This technique is routinely employed in all autologous settings and is critical for cord blood transplantation. A variety of cryopreservatives have been used with multiple freezing and thawing techniques as outlined in the later chapters. Freezing efficiency has been proven repeatedly and the ability of long-term stored marrow to repopulate has been established. Standard approaches outlined here are used in many labs as the field continues to evolve. Am. J. Hematol. 82:463-472, 2007. V V C 2007 Wiley-Liss, Inc.

show abstract

Comparison of CD34+ cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy

Cited by 38 publications

References 22 publications

Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment

Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment

Effect of prior chemotherapy on hematopoietic stem cell mobilization

Cryopreservation of hematopoietic stem cells

Contact Info

Product

Resources

About